New study aims to pinpoint optimal timing of vasopressin in septic shock
NCT ID NCT06709573
First seen Jun 26, 2026 · Last updated Sep 01, 2026 · Updated 3 times
Summary
This study tests whether giving the drug vasopressin earlier or later during septic shock leads to better outcomes. Researchers will use a computer alert system to randomly assign 300 ICU patients to early or standard timing. The goal is to see if the timing can be reliably controlled and to compare patient results.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- vasopressin
- What this could lead to
- If successful, this could help doctors decide the best time to add vasopressin for septic shock patients, potentially improving survival and reducing complications.
- What could go wrong
- This is a pilot study focused on feasibility, not a large outcome trial. The results may not change practice immediately, and individual patient responses can vary.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 300 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2025
- Expected to finish
-
May 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥ 18 Years * Diagnosis of Septic Shock * Admitted to Cleveland Clinic Main Campus Medical ICU * Receiving continuous infusion of norepinephrine at a dose \> 5 mcg/min at time of enrollment Exclusion Criteria: * Administration of any other vasoactive agent other than norepinephrine at time of enrollment * Initiation of vasopressin by provider outside of the context of study when NE \< 10 mcg/min (before BPA firing)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Sepsis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Cleveland Clinic
RECRUITINGCleveland, Ohio, 44095, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can warming the body help sepsis patients who cannot make a fever?
- Can a simple ultrasound measurement reveal heart strain in sepsis?
- Chilling fever: can cooling septic shock patients save lives?
- Clotting clues: simple blood test eyed to catch sepsis before it turns deadly
- Bedside eye scans may reveal hidden blood flow problems in septic shock
- Can two blood markers catch sepsis before it turns deadly?